Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib

World Journal of Surgical Oncology

Volumn 11, Issue , 2013, Pages

  Kermiche Rahali, Sabrina ^a   Di Fiore, Aude ^a   Drieux, Fanny ^a   Di Fiore, Frédéric ^a   François, Arnaud ^a   Scotté, Michel ^a  

^a ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

Hepatocellular carcinoma; Liver resection; Sorafenib

Indexed keywords

SORAFENIB;

ADVANCED CANCER; AGED; ARTICLE; CANCER PATIENT; CASE REPORT; CLINICAL ASSESSMENT; DIARRHEA; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; HAND FOOT SYNDROME; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER LOBECTOMY; LIVER RESECTION; MALE; MOLECULARLY TARGETED THERAPY; PALLIATIVE THERAPY; PORTAL VEIN; PORTAL VEIN THROMBOSIS; RECANALIZATION; TREATMENT DURATION; TUMOR NECROSIS; TUMOR VOLUME;

AGED; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; MALE; NIACINAMIDE; PHENYLUREA COMPOUNDS; PORTAL VEIN; PROTEIN KINASE INHIBITORS; REMISSION INDUCTION; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 84881534216     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-11-171     Document Type: Article

References (16)

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003, 362:1907-1917. 10.1016/S0140-6736(03)14964-1, 14667750.
2. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodés J, EASL Panel of Experts on HCC Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001, 35:421-430. 10.1016/S0168-8278(01)00130-1, 11592607, EASL Panel of Experts on HCC.
3. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002, 35:519-524. 10.1053/jhep.2002.32089, 11870363.
4. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ, Panel of Experts in HCC-Design Clinical Trials Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008, 100:698-711. 10.1093/jnci/djn134, 18477802, Panel of Experts in HCC-Design Clinical Trials.
5. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, SHARP Investigators Study Group Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390. 10.1056/NEJMoa0708857, 18650514, SHARP Investigators Study Group.
6. Curtit E, Thiery-Vuillemin A, Nguyen T, Heyd B, Pivot X, Di Martino V, Borg C. Complete histologic response induced by sorafenib in advanced hepatocellular carcinoma: a case report. J Clin Oncol 2011, 20:330-332.
7. Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236. 10.1002/hep.20933, 16250051, Practice Guidelines Committee, American Association for the Study of Liver Diseases.
8. Torzilli G, Belghiti J, Kokudo N, Takayama T, Capussotti L, Nuzzo G, Vauthey JN, Choti MA, De Santibanes E, Donadon M, Morenghi E, Makuuchi M. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations?: an observational study of the HCC East-west study group. Ann Surg 2013, 257:929-937. 10.1097/SLA.0b013e31828329b8, 23426336.
9. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumour progression and angiogenesis. Cancer Res 2004, 64:7099-7109. 10.1158/0008-5472.CAN-04-1443, 15466206.
10. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009, 10:25-34. 10.1016/S1470-2045(08)70285-7, 19095497.
11. Irtan S, Chopin-Laly X, Ronot M, Faivre S, Paradis V, Belghiti J. Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection. Liver Int 2011, 31:740-743. 10.1111/j.1478-3231.2010.02441.x, 21457447.
12. Barbier L, Muscari F, Le Guellec S, Pariente A, Otal P, Suc B. Liver resection after downstaging hepatocellular carcinoma with sorafenib. Int J Hepatol 2011, 2011:7910-7913.
13. Tarantino L, Francica G, Sordelli I, Esposito F, Giorgio A, Sorrentino P, de Stefano G, Di Sarno A, Ferraioli G, Sperlongano P. Diagnosis of benign and malignant portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma: color Doppler US, contrast-enhanced US, and fine needle biopsy. Abdom Imaging 2006, 31:537-544. 10.1007/s00261-005-0150-x, 16865315.
14. Piscaglia F, Gianstefani A, Ravaioli M, Golfieri R, Cappelli A, Giampalma E, Sagrini E, Imbriaco G, Pinna AD, Bolondi L, Bologna Liver Transplant Group Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation. Liver Transpl 2010, 16:658-667. Bologna Liver Transplant Group.
15. Li Q, Xu B, Fu L, Hao XS. Correlation of four vascular specific growth factors with carcinogenesis and portal vein tumor thrombus formation in human hepatocellular carcinoma. J Exp Clin Cancer Res 2006, 25:403-409.
16. Barbier L, Fuks D, Pessaux P, Muscari F, Le Treut YP, Faivre S, Belghiti J. Safety of liver resection for hepatocellular carcinoma after sorafenib therapy: a multicenter case-matched study. Ann Surg Oncol 2013,